drugset
drugset / Trial / NCT04750382

A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer

NCT04750382 ↗

Phase 1/2 Unknown 31 enrolled Taizhou Hanzhong Biomedical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

HX008 is a humanized monoclonal antibody targeting PD-1 on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors. In this study, the safety and preliminary efficacy of HX008+cisplatin+gemcitabine for the treatment of patients with metastatic triple-negative breast cancer will be evaluated.

Timeline

Start
2019-07-15
Primary completion
2020-12-01
Completion
2021-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 75 mg/m2 —
Subject Gemcitabine Small molecule 1250 mg/m2 —
Subject Pucotenlimab Monoclonal antibody 3 mg/kg —

Indications

triple-negative breast carcinoma